252 related articles for article (PubMed ID: 24412066)
21. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
Yang Z; Fang Y; Park H
Bioorg Med Chem Lett; 2017 Jun; 27(11):2515-2519. PubMed ID: 28408218
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity.
Chen J; Sang Z; Li L; He L; Ma L
Mol Divers; 2017 Aug; 21(3):637-654. PubMed ID: 28656523
[TBL] [Abstract][Full Text] [Related]
25. The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists.
Porter DW; Bradley M; Brown Z; Canova R; Charlton S; Cox B; Hunt P; Kolarik D; Lewis S; O'Connor D; Reilly J; Spanka C; Tedaldi L; Watson SJ; Wermuth R; Press NJ
Bioorg Med Chem Lett; 2014 Jan; 24(1):72-6. PubMed ID: 24332493
[TBL] [Abstract][Full Text] [Related]
26. Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A).
Blad CC; van Veldhoven JP; Klopman C; Wolfram DR; Brussee J; Lane JR; Ijzerman AP
J Med Chem; 2012 Apr; 55(7):3563-7. PubMed ID: 22420767
[TBL] [Abstract][Full Text] [Related]
27. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.
Venkatesan G; Paira P; Cheong SL; Federico S; Klotz KN; Spalluto G; Pastorin G
Eur J Med Chem; 2015 Mar; 92():784-98. PubMed ID: 25633494
[TBL] [Abstract][Full Text] [Related]
28. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Bamaung NY; Palazzo F; Zhang Q; Kovar P; Osterling DJ; Hu X; Wilsbacher JL; Johnson EF; Bouska J; Wang J; Bell RL; Davidsen SK; Sheppard GS
Bioorg Med Chem Lett; 2007 Oct; 17(19):5406-9. PubMed ID: 17689078
[TBL] [Abstract][Full Text] [Related]
29. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
30. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
[TBL] [Abstract][Full Text] [Related]
31. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
[TBL] [Abstract][Full Text] [Related]
33. Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.
Kim H; Kim M; Oh K; Lee S; Lim S; Lee S; Kim YH; Suh KH; Min KH
Eur J Med Chem; 2023 Oct; 258():115584. PubMed ID: 37356344
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
35. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
[TBL] [Abstract][Full Text] [Related]
36. Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.
Griffith DA; Hargrove DM; Maurer TS; Blum CA; De Lombaert S; Inthavongsay JK; Klade LE; Mack CM; Rose CR; Sanders MJ; Carpino PA
Bioorg Med Chem Lett; 2011 May; 21(9):2641-5. PubMed ID: 21295475
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of novel pyrazolo[3,4-d]pyrimidine derivatives as potential anti-breast cancer agents.
Abd El Hamid MK; Mihovilovic MD; El-Nassan HB
Eur J Med Chem; 2012 Nov; 57():323-8. PubMed ID: 23085106
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antitumor properties of pyrazolo [3,4-D] pyrimidine derivatives.
Witkiewicz K; MachoĊ Z; Mordarski M; Wieczorek J
Pol J Pharmacol Pharm; 1987; 39(6):715-20. PubMed ID: 3503990
[TBL] [Abstract][Full Text] [Related]
39. Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-
Fang Y; Zhang S; Li M; Xiong L; Tu L; Xie S; Jin Y; Liu Y; Yang Z; Liu R
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):50-58. PubMed ID: 31656107
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of pyrazolo[4',3':5,6]pyrano[2,3-d]pyrimidine derivatives for antiviral evaluation.
Shamroukh AH; Zaki ME; Morsy EM; Abdel-Motti FM; Abdel-Megeid FM
Arch Pharm (Weinheim); 2007 May; 340(5):236-43. PubMed ID: 17464958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
